Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Biomaterials

• Publication date

  2017-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.biomaterials.2016.11.051PMID 27923197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.

  2016cited by this paper
• Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

  2015cited by this paper
• N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone.

  2015cited by this paper
• Production of Recombinant Human Growth Hormone Conjugated with a Transcytotic Peptide in Pichia pastoris for Effective Oral Protein Delivery

  2015cited by this paper
• The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity

  2015cited by this paper
• Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein.

  2015cited by this paper
• Biological drug products : development and strategies

  2014cited by this paper
• Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone.

  2014cited by this paper
• Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

  2014cited by this paper
• Formulation, Drug Product, and Delivery: Considerations for Fc‐Fusion Proteins

  2013cited by this paper
• Pharmacokinetic studies of protein drugs: past, present and future.

  2013cited by this paper
• Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein

  2013cited by this paper
• Fusion protein linkers: property, design and functionality.

  2013cited by this paper
• Effects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins.

  2011cited by this paper
• Strategies and challenges for the next generation of therapeutic antibodies

  2010cited by this paper
• Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats.

  2010influential reference
• Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations

  2010cited by this paper
• Transferrin Receptor–Mediated Transcytosis in Intestinal Epithelial Cells for Gastrointestinal Absorption of Protein Drugs

  2010cited by this paper
• Neonatal Fc Receptor: From Immunity to Therapeutics

  2010cited by this paper
• The value of IGF1 estimation in adults with GH deficiency.

  2009cited by this paper
• Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability.

  2009cited by this paper
• The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity

  2009cited by this paper
• Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid.

  2008cited by this paper
• Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn

  2008cited by this paper
• Engineering peptide linkers for scFv immunosensors.

  2008cited by this paper
• PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humans

  2008cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Target-mediated drug disposition and dynamics.

  2006cited by this paper
• Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.

  2006cited by this paper
• Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fcgamma-receptor.

  2004cited by this paper
• Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.

  2003cited by this paper
• Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies.

  2002cited by this paper
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*

  2001cited by this paper
• Bispecific human IgG by design.

  2001cited by this paper
• The IgG Fc Contains Distinct Fc Receptor (FcR) Binding Sites: The Leukocyte Receptors FcγRI and FcγRIIa Bind to a Region in the Fc Distinct from That Recognized by Neonatal FcR and Protein A1

  2000cited by this paper
• The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A.

  2000cited by this paper
• Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line.

  1999cited by this paper
• Formulation

  1997cited by this paper
• Combined growth hormone (GH) and insulin-like growth factor-I (IGF-I) treatment is more effective than GH or IGF-I alone at enhancing recovery from neonatal malnutrition in rats.

  1995cited by this paper
• Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.

  1995cited by this paper
• Human growth hormone but not human insulin-like growth factor-I enhances recovery from neonatal malnutrition in rats.

  1995cited by this paper
• Differential regulation of the insulin-like growth factors (IGF-I and -II) and IGF binding proteins during malnutrition in the neonatal rat.

  1991cited by this paper
• A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum.

  1980cited by this paper

• Novel, Stable, and Well-Secreted Single-Chain Fc Forms of Programmed Death-1 Immune Checkpoint Inhibitor Efficiently Block PD-1/PD-L1 Interaction.

  2026cites this paper
• Novel perspectives on growth hormone regulation of ovarian function: mechanisms, formulations, and therapeutic applications

  2025cites this paper
• A KRASG12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor

  2025cites this paper
• Phase 1 Study and Population PK/PD Modeling of Long-Acting Growth Hormone, GB08, to Guide Pediatric Dosing.

  2025cites this paper
• Targeting fusion proteins of the interleukin family: a promising new strategy for the treatment of autoinflammatory diseases.

  2023cites this paper
• Characterization of Small Molecule-Protein Interactions Using SPR Method.

  2023cites this paper
• Design and production of a novel chimeric human growth hormone superagonist fused to human Fc domain

  2022cites this paper
• A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives

  2021cites this paper
• In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance

  2021cites this paper
• Pharmacokinetics of Recombinant Human Growth Hormone (rhGH) in Beagles by ELISA

  2020cites this paper
• Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics

  2019cites this paper